Hypertension is a very common condition among recipients of transplanted organs, and is often related to immunosuppressive therapy. In many transplant centres, calcium antagonists are often used as first-line antihypertensive drug therapy, not only because of efficacy in lowering blood pressure, but also because certain members of the class have a 'beneficial' drugdrug interaction with cyclosporin, which decreases the cost of administering this very expensive immunosuppressant. Diuretics are often used both for blood pressKeywords: transplant recipients; cyclosporin; calcium antagonists
Introduction
The elevation of blood pressure (BP) which commonly occurs in transplant recipients increases the risk of cardiovascular complications in these patients, just as hypertension increases risk in patients who have all of their own original organs intact. 1, 2 Probably because of the elevated absolute risk, it has taken fewer patients to demonstrate the benefits of lowering elevated BPs in transplant recipients than in pretransplant patients. 3 Because of this higher absolute risk, there are special considerations which arise in the treatment of hypertension in transplant recipients which are not present in patients with all native organs present. 1 When the issue of 'traditional drug therapy of hypertension in the transplant recipient' is addressed, multiple questions come to mind which must be answered before recommendations for a specific patient can be given. Several of these questions include: (1) 'Which are the "traditional drugs" that should be considered?' (2) 'Which organ was transplanted?' which in the USA is a way of asking also, 'Which physicians are caring for the patient?' (3) 'Which of the common sequelae of hypertension are we attempting to prevent with our treatment?' The answers to these questions must be sought before individualising therapy, because patients with different transplanted organs should be protected from the ravages of high BP, which manifests in different ways. 1 For many physicians and some health care policymakers, the roster of traditional drugs which are often used to treat hypertension in transplant recipients includes (in chronological order of introduction): diuretics, beta-blockers, calcium antagonists, angiotensin-converting enzyme (ACE)-inhibitors, alpha 1 -blockers, alpha-beta-blockers, and a few other classes of drugs. Some with a longer historical viewpoint would point to only the first two of these as being 'traditional' antihypertensive drugs, and a few suggest that the calcium antagonists, ACE-inhibitors, alpha-blockers, and the alphabeta-blockers are 'experimental therapies' which may lower BP, but have not been proven in longterm trials against placebo to affect the morbidity and mortality associated with hypertension.
The issue of which organ was transplanted matters, at least in the USA, because the 'organ-orientation' of the treating physician often dictates which type of antihypertensive drug therapy is preferred. Many nephrologists are particularly comfortable treating hypertension in renal transplant recipients with diuretics, since their site of action is mainly in 'their' organs; 4 some nephrologists have recently become quite adept at treating hypertension in diabetics with ACE-inhibitors, and use this class of drugs quite frequently because of their proven benefit in reducing renal endpoints in Type I diabetics. 5 If the transplant recipient has a new heart, there is often a cardiologist involved in the treatment of hypertension, and many cardiologists are more likely to have experience with beta-blockers or calcium antagonists, since many of the patients they routinely see have hypertension and angina pectoris. 6, 7 Hepatologists generally have less predictable tendencies regarding antihypertensive therapies, but they often avoid certain medications known to cause elevation of liver enzymes or hepatic failure. 8 The organ-orientation of the treating physician is also important because it often allows identification of the long-term goal of the treatment of the patient. While all physicians (with the possible exception of one in Michigan) attempt to prevent death in their patients, the near-term goal of the treatment of hypertension is usually more modest. Most physicians working in transplantation centres are acutely aware of the need to avoid re-transplantation, because obtaining a second donor organ for a given patient is typically very difficult. Most nephrologists therefore work very hard at avoiding renal impairment in renal transplant recipients, [9] [10] [11] but some have begun to realise that long-term survival in renal transplant recipients is often limited by the development of cardiovascular disease. 12 Many cardiologists and cardiac surgeons attempt to avoid the early atherosclerosis and left ventricular dysfunction which are commonly seen in transplanted hearts when the BP is not well controlled. 6, 7 Each of the individual classes of anti-hypertensive agents used to treat hypertension in transplant recipients have advantages and disadvantages associated with their use. Many wise physicians attempt to match these to the individual patient, and choose the 'proper' agent for each patient. Sadly, there are few 'head-to-head' comparative clinical trials which give a clear-cut answer as to which class of agents might be best, 13 although strong opinions have often been expressed about the superiority of one class or one agent over others in specific patient populations, as discussed below.
Diuretics
The diuretics have several advantages in treating the hypertension which often arises in transplant recipients. They very effectively counter the sodium retention often associated with immunosuppressive agents (both cyclosporin and corticosteroids). Diuretics effectively reduce the volume overload seen in patients with chronic renal impairment or congestive heart failure (eg, in renal and/or cardiac transplant recipients). Perhaps most importantly, the effects of nearly all antihypertensive agents are potentiated (and further BP lowering occurs) when a small dose of diuretic is added to a not-quiteadequately effective regimen. And lastly, there is a small to mild amount of published literature which documents the antihypertensive effects of diuretics in transplant recipients. Although diuretics may not be commonly used as first-line treatment in many transplant centres, it is common practice to add diuretics when the chosen first-line treatment is not sufficiently lowering the BP. 9 There are, however, some concerns and possible disadvantages of diuretics, which limits their use as first-line agents in some centres. Heart transplant centres are understandably wary of the potential of diuretics to aggravate (or cause) hypokalaemia and hypomagnesaemia (which have been associated in some studies with cardiac dysrhythmias), and dyslipidaemia (which is typically a major problem for most cardiac transplant recipients 7 ). Renal transplant centres are perhaps more commonly using diuretics, but there is still concern about the interpretation of serum BUN/creatinine measurements, especially in the setting of pre-renal azotemia, where the volume contraction can be (often erroneously) interpreted as worsened renal impairment. There is also some concern about diureticinduced hyperuricaemia and rare cases of urate nephropathy.
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Beta-blockers
In a few centres, there is some enthusiasm for the use of beta-blockers in transplant recipients. These drugs are very effective in controlling tachycardia and sympathetic activation, 14 which can be a problem in the immediate post-operative transplant recipient treated acutely with cyclosporin. Some have suggested that these drugs cause a reduction in the severity and frequency of cyclosporin-associated headache. 15 There is a moderate amount of published literature supporting their efficacy and safety in the treatment of transplant-related hypertension. 7 There are several concerns about beta-blockers which limit their utility, however. They are at least relatively contraindicated in many patients, including those with asthma, diabetes mellitus (especially those who are insulin-dependent and are tightlycontrolled, due to prolongation of hypoglycaemic coma), and major peripheral vascular disease. There is concern about their use in patients with bradycardia, although this seldom is a reason not to start these medications. Heart transplant centres are generally a bit wary of beta-blockers, because of the unpredictable effects on the atrial rate of the denervated heart and because of the hypertriglyceridaemia and hypo-HDL-cholesterolaemia which often are seen during long-term use. The effects of betablockers on renal function are generally neither positive nor negative, and so they are not often the drugs of first choice in many renal transplant centers.
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Calcium antagonists
In many transplant centres, calcium antagonists are routinely used as first-line treatment for the hypertensive transplant recipient. 11, 16, 17 There have been extensive physiological and pharmacological studies of many calcium antagonists in micropuncture studies, animal studies, and even a few in humans which demonstrate the vasodilatory effect of many calcium antagonists on the afferent arteriole in the renal circulation, which is thought to be the site of action of cyclosporin. [18] [19] [20] Thus some have characterised calcium antagonists as 'specific therapy' for the cyclosporin-related vasoconstriction of the afferent arteriole. 1, 10, 11, 18, 21 Several small prospective studies of renal transplant recipients have shown an improvement in many parameters in the calcium antagonist-treated group. [22] [23] [24] [25] Furthermore, there are some very intriguing data from the Stanford heart transplant group which suggests that a calcium antagonist (short-acting diltiazem, taken thrice daily) may limit the early and very aggressive atherogenesis process which is very often seen in heart transplant recipients. 26 Although the study was, by design, unblinded and a randomised consecutive series without placebo-control, patients catheterised 2 years after initiation of treatment with that preparation of diltiazem showed no increase in coronary arterial diameter, which was highly statistically significantly different from the decrease seen in the control (untreated) patients. The number of patients who developed stenoses Ͼ50% were small, but higher in the control than diltiazem-treated group (7 vs 2); all five episodes of cardiovascular death or retransplantation occurred in control patients. Further follow-up in this cohort, and results of other randomised trials will be of great interest to cardiac transplantation centres. There are some very early data suggesting that at least one calcium antagonist (verapamil) may have some intrinsic immunosuppressive activity, but the long-term importance of this finding still remains to be defined. Perhaps the most important reason why calcium antagonists are used as first-line therapy for hypertensive transplant recipients (at least in the USA, where medicine is now being considered 'just another business') is because of a beneficial drug-drug interaction between cyclosporin and diltiazem, 27, 28 verapamil, 29 felodipine, 30 or nicardipine. 31, 32 Because cyclosporin is itself such an expensive (but very necessary and useful) immunosuppressive agent used nearly universally in transplant programmes, its cost is often the major expenditure for patients once the surgical procedure is completed. Because the calcium antagonists interfere with metabolism and excretion of cyclosporin, 33 the concomitant administration of one of the calcium antagonists decreases the dose of cyclosporin necessary to achieve a given plasma concentration, which in turn decreases the cost of maintaining a transplant patient in the long term. The cost of the calcium antagonists is but a mere fraction of the cost savings realised by the 'pharmacoeconomically beneficial' drug-drug interaction, and many centres have adopted the practice of treating not only their hypertensive but their normotensive patients with a prophylactic regimen of a suitable calcium antagonist which confers these fiscal benefits. 33 Despite the general enthusiasm for the use of calcium antagonists in hypertensive transplant recipients, there are some concerns about their use. Their administration to a recently transplanted patient often leads to unpredictable plasma cyclosporin levels, and great care is necessary to monitor these levels and assure that the patient is receiving enough (but not too much) cyclosporin. There is some concern about potentiating atrio-ventricular block with negatively chronotropic agents (eg, diltiazem and verapamil). Lastly (and perhaps the biggest challenge) is the realisation (in many centres) that patients often develop adverse effects apparently attributable to these drugs which are not commonly seen in non-transplanted patients; about 30% of transplant recipients wish to change their antihypertensive medication during chronic follow-up due to oedema, headache, or fatigue, most of which resolves after switching.
ACE-inhibitors and angiotensin II receptor antagonists
One class of effective antihypertensive drugs which apparently is used less commonly in transplant recipients than in patients with all native organs intact are the ACE inhibitors. Representatives of this class of drug have been shown to limit the progression of renal impairment in diabetics 5 and other glomerular diseases, and they are widely used by endocrinologists and nephrologists 34 who treat diabetes, the most common underlying disease which leads to dialysis in the USA. There are several members of this class of drugs which have been shown to improve both symptoms and survival in congestive heart failure and in the post-MI state. The ACEinhibitors also tend to mitigate the putative adverse metabolic effects of diuretics. Despite all these possible advantages, there is little positive literature on the hypotensive effects of ACE-inhibitors in transplant recipients.
Most of the literature about ACE-inhibitors in transplant recipients points to their limited efficacy in lowering BP when used as monotherapy. [35] [36] [37] [38] The few successful reports have generally used ACEinhibitors in combination with diuretics or even calcium antagonists. 39 Kidney transplant centres have tended to avoid the ACE-inhibitors for post-transplant patients because of the potential for worsening hyperkalaemia, azotemia (which is typically prerenal and transient), non-anion-gap acidosis, and (perhaps the most dreaded), precipitating acute renal failure if there is transplant renal artery stenosis.
There are even fewer data in humans which reflect the effects of angiotensin II receptor antagonists, the newest class of antihypertensive agents, on BP in transplant recipients. The results of a few animal studies have been mildly encouraging, 40 and it is possible that these newer drugs may eventually have a role (although perhaps more limited than even ACE-inhibitors) in transplanted patients.
Alpha 1 -blockers
There is little literature about the use of alpha 1 -blockers in the treatment of post-transplant hypertension. Centres which have used these drugs have concerns about their propensity to cause orthostatic hypotension (which is typically worse in diabetics, who are a large fraction of the renal transplant population); there have also been patients who develop tolerance (especially with prazosin), and require higher doses of drug over time to achieve BP control.
Alpha-beta-blockers
Most of the foregoing discussion about beta-blockers is also true of the alpha-beta-blocking agents. Labetalol, however, has developed a special place in the treatment of hypertension in liver transplant recipients, and is typically used as first-line therapy for these patients at the Mayo Clinic, where they have a very large experience. 1 The Hypertension Division of the Mayo Clinic has been involved in the treatment of liver transplant recipients for a very long time, and they have reported great success with the use of labetalol, first parenterally when necessary, and then orally for chronic use. This apparent success story is a bit at odds with the known (albeit rare) hepatic toxicity of labetalol 41 (which has been linked to one of the four diastereomers, dilevalol 42 ).
Other observations
Perhaps the most interesting aspect of treating hypertension in transplant recipients is the prevalence, especially in patients given cyclosporin. Some centres estimate that 70-85% of cyclosporintreated patients eventually require antihypertensive drug therapy. 9 There is hope that tacrolimus 43, 44 (FK506) or new preparations of cyclosporin 20 will limit the need for antihypertensive drug therapy in the future.
Despite the foregoing discussion of initial monotherapies for antihypertensive drug therapy in transplant recipients, there is a rather large fraction of patients who receive more than one antihypertensive agent. Often two or more drugs are needed to control BP, but even more interesting is the fact that, unlike non-transplant patients who often do well with a given drug for many years, experience in many centres now indicates that many transplant patients switch antihypertensive drug therapies at three or more times the rate than their non-transplanted hypertensives. The reasons why so many transplant recipients switch antihypertensive drugs so often is not yet clear. It may be partially related to adverse effects (oedema, fatigue, etc) which seem to develop more often and to a greater degree in the transplant recipients, but these patients also have a higher severity of illness, are hospitalised more frequently, and are seen by many more physicians (with different opinions about how hypertension might best be managed!) than non-transplanted patients. There are therefore many more opportunities to change medications in transplant recipients than in non-transplanted hypertensives.
Conclusions
Despite current uncertainties about which drug or drug class might be best for the treatment of hypertension in transplant recipients, it is abundantly clear that, by giving antihypertensive drug therapy, it is possible to bring the BP under control in the 70-85% of transplant recipients who develop elevated BPs. No large, multicentre, randomised, formal studies have shown any one class of traditional antihypertensive drug therapy to be more advantageous than another, 13 but many transplant centres in the USA use a calcium antagonist first, because of an economically-beneficial drug-drug interaction. Despite international exhortation on behalf of beginning a randomised comparison between drugs or drug classes, it is likely that (at least in the USA), this economic issue is so important that a clinical trial is not feasible. Although there are many advantages and disadvantages of each class of antihypertensive agent, the drug(s) used to treat post-transplant hypertension depend on the transplanted organ, the training of the physician, and other characteristics of the individual patient to be treated.
